Fiera Capital Corp Purchases 15,463 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiera Capital Corp lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 141,198 shares of the company’s stock after buying an additional 15,463 shares during the period. Fiera Capital Corp owned approximately 0.17% of IDEXX Laboratories worth $58,377,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Marks Group Wealth Management Inc grew its position in IDEXX Laboratories by 8.6% during the fourth quarter. Marks Group Wealth Management Inc now owns 11,009 shares of the company’s stock valued at $4,552,000 after buying an additional 869 shares during the period. Capital Advisors Inc. OK purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $205,000. L. Roy Papp & Associates LLP boosted its stake in IDEXX Laboratories by 31.9% in the fourth quarter. L. Roy Papp & Associates LLP now owns 620 shares of the company’s stock valued at $256,000 after acquiring an additional 150 shares during the last quarter. Summit Trail Advisors LLC grew its position in shares of IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock valued at $335,000 after acquiring an additional 26 shares during the period. Finally, Equitable Trust Co. purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $676,000. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,330 shares of company stock valued at $6,161,276. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDXX opened at $457.35 on Thursday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock has a market cap of $37.45 billion, a PE ratio of 42.86, a P/E/G ratio of 3.47 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $429.67 and its 200-day moving average price is $453.23.

Wall Street Analyst Weigh In

IDXX has been the topic of several research analyst reports. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.